Catalyst Wire Dossier Catalyst Wire Dossier

ASTX030 (Azacitidine and Cedazuridine)

Azacitidine and Cedazuridine · Taiho Oncology, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ASTX030 (Azacitidine and Cedazuridine), covering 2026-04-03 to 2026-04-03. Get the full timeline:

Most recent: Clinical Trial Update: A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) [Phase 2, Phase 3]

See pricing